IP Library Granted Patent US 10,968,496
Granted Patent B2
US 10,968,496 · App. 16/154,618 · Granted Apr 6, 2021

Recombinant Vibrio natriegens organisms having a modified outer membrane

Inventors: Matthew T Weinstock (San Diego, CA); Daniel G. Gibson (Carlsbad, CA); Daniel Strimling (La Jolla, CA)
Assignee: Codex DNA, Inc.
C12R1/63C12N9/1029C12N15/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,968,496
App. No.
16/154,618
Granted
Apr 6, 2021
Kind
B2
Abstract

The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.

Claims (21)

1. A recombinant Vibrio natriegens organism comprising:

a deletion, inactivation, or disruption of the lpxL gene or the lpxM gene,

wherein the organism produces substantially less endotoxin compared to a corresponding organism not comprising the deletion, inactivation, or disruption and cultivated under the same conditions;

wherein the recombinant Vibrio natriegens organism exhibits a growth rate of at least 60% of the growth rate of the corresponding organism when cultivated under the same conditions; and

wherein the organism has an endotoxin level of less than 50 EU/ml of purified lipopolysaccharide.

2. The Vibrio sp. organism of claim 1 , wherein the organism has an outer membrane comprising a modified lipopolysaccharide component.

3. The Vibrio sp. organism of claim 1 , wherein the organism does not comprise a deletion, inactivation, or disruption in any gene selected from the group consisting of gutQ, kdsD, pagP, and lpxP.

4. The Vibrio natriegens organism of claim 1 , having a growth rate of at least 70% the growth rate of a corresponding unmodified Vibrio natriegens organism under identical conditions.

5. The Vibrio natriegens organism of claim 1 , having an average endotoxin level of less than 1 EU/ml measured in an in vitro assay.

6. The Vibrio natriegens organism of claim 1 , having a doubling time of 55-70 minutes at 30° C.

7. The Vibrio natriegens organism of claim 1 , wherein the growth rate is measured over a period of 8 hours.

8. The Vibrio natriegens organism of claim 1 , wherein the growth rate is measured over a period of 12 hours.

9. The Vibrio natriegens organism of claim 2 , wherein the organism has a growth rate of at least 60% the growth rate of a wild type Vibrio natriegens under the same growth conditions, and has an endotoxin level of less than 10 EU/ml, and a specific growth rate of at least 0.60 at 30° C. in LBv2 media.

10. The Vibrio natriegens organism of claim 1 , wherein the organism comprises an exogenous nucleic acid for the production of the exogenous nucleic acid or for the production of an encoded heterologous protein or peptide.

11. The recombinant Vibrio natriegens organism of claim 1 , having an endotoxin level of less than 10 EU/ml measured in an in vitro assay.

12. The recombinant Vibrio natriegens organism of claim 11 , wherein the organism exhibits a growth rate of at least 80% of the growth rate of the corresponding organism when cultivated under the same conditions.

13. The recombinant Vibrio natriegens organism of claim 12 , having an endotoxin level of less than 1 EU/ml measured in an in vitro assay.

14. A kit comprising a recombinant Vibrio natriegens organism of claim 1 .

15. The kit of claim 14 , further comprising a vector for cloning a nucleic acid sequence or for expressing a protein or peptide.

16. The kit of claim 14 , further comprising a positive control vector for verifying transformation.

17. The kit of claim 14 , further comprising a growth medium for the recombinant Vibrio natriegens organism.

Assignments (8)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (TERM) Recorded Jul 16, 2024
From: MIDCAP FINANCIAL TRUST
To: TELESIS BIO INC. (FORMERLY KNOWN AS CODEX DNA, INC.); ETONBIO, INC.
Reel/Frame 068390/0070 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (REVOLVING) Recorded Jul 16, 2024
From: MIDCAP FUNDING IV TRUST
To: TELESIS BIO INC. (FORMERLY KNOWN AS CODEX DNA, INC.); ETONBIO, INC.
Reel/Frame 068390/0001 →
CHANGE OF NAME Recorded Apr 19, 2023
From: CODEX DNA, INC.
To: TELESIS BIO INC.
Reel/Frame 063379/0581 →
SECURITY INTEREST (TERM) Recorded Aug 18, 2022
From: CODEX DNA, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061208/0080 →
SECURITY INTEREST (REVOLVING) Recorded Aug 18, 2022
From: CODEX DNA, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 061208/0063 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2020
From: OXFORD FINANCE LLC
To: SYNTHETIC GENOMICS, INC.; GENOVIA BIO, LLC; GREEN RESOURCES, LLC; SGI-DNA, INC.; SYNTHETIC GENOMICS VACCINES, INC.
Reel/Frame 054372/0822 →
CHANGE OF NAME Recorded May 19, 2020
From: SGI-DNA, INC.
To: CODEX DNA, INC.
Reel/Frame 052705/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2019
From: SYNTHETIC GENOMICS, INC.
To: SGI-DNA, INC.
Reel/Frame 049602/0502 →
Continuity (2)
Provisional Application 62588755 · Nov 20, 2017
Related Publication 20190153554A1 · May 23, 2019
Cited By (2)
US 12,331,326 US 12,442,006